225 related articles for article (PubMed ID: 17926655)
21. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.
Hansen BR; Haugaard SB; Iversen J; Nielsen JO; Andersen O
Scand J Infect Dis; 2004; 36(4):244-53. PubMed ID: 15198179
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
Introcaso CE; Hines JM; Kovarik CL
J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
[TBL] [Abstract][Full Text] [Related]
23. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?
Behrens GM; Stoll M; Schmidt RE
Drug Saf; 2000 Jul; 23(1):57-76. PubMed ID: 10915032
[TBL] [Abstract][Full Text] [Related]
24. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
[TBL] [Abstract][Full Text] [Related]
25. [Metabolic changes in HIV infected patient].
Castelo Filho A; Abrão P
Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):5-7. PubMed ID: 17435849
[No Abstract] [Full Text] [Related]
26. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
27. Fat, sugar and drugs on the French Riviera.
Lands L
GMHC Treat Issues; 1999 Mar; 13(3):9-11. PubMed ID: 11366205
[TBL] [Abstract][Full Text] [Related]
28. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.
Tanwani LK; Mokshagundam SL
South Med J; 2003 Feb; 96(2):180-8; quiz 189. PubMed ID: 12630645
[TBL] [Abstract][Full Text] [Related]
29. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
Kotler DP
J Acquir Immune Defic Syndr; 2008 Sep; 49 Suppl 2():S79-85. PubMed ID: 18725816
[TBL] [Abstract][Full Text] [Related]
30. [Facial lipodystrophy in patients with HIV infections troublesome to treat].
Walther RA
Lakartidningen; 2002 Sep; 99(39):3826-9. PubMed ID: 12395531
[TBL] [Abstract][Full Text] [Related]
31. HIV-associated facial lipoatrophy.
James J; Carruthers A; Carruthers J
Dermatol Surg; 2002 Nov; 28(11):979-86. PubMed ID: 12460289
[TBL] [Abstract][Full Text] [Related]
32. Metabolic complications of HIV therapy in children.
McComsey GA; Leonard E
AIDS; 2004 Sep; 18(13):1753-68. PubMed ID: 15316336
[No Abstract] [Full Text] [Related]
33. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
34. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.
Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F
New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090
[TBL] [Abstract][Full Text] [Related]
35. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
Holstein A; Plaschke A; Egberts EH
Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
[TBL] [Abstract][Full Text] [Related]
36. [HIV lipodystrophy syndrome: a new challenge to the endocrinologist].
Valente O; Valente AM
Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):3-4. PubMed ID: 17435848
[No Abstract] [Full Text] [Related]
37. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
[TBL] [Abstract][Full Text] [Related]
38. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
[TBL] [Abstract][Full Text] [Related]
39. Report from the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.
Currier J
AIDS Clin Care; 2007 Oct; 19(10):91. PubMed ID: 18398999
[No Abstract] [Full Text] [Related]
40. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
Tarr PE; Telenti A
Antivir Ther; 2007; 12(7):999-1013. PubMed ID: 18018758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
